Skip to content
false
Blog

Oncology

100% sourced from leading minds on the front lines of research

Latest Posts

  • Read: FDA's Vision for Multiregional Clinical Trials in Oncology FDA's Vision for Multiregional Clinical Trials in Oncology

    Clinical Trials - Regulatory - Oncology

    FDA's Vision for Multiregional Clinical Trials in Oncology

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1744844126301, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Harpreet Singh, MD avatar

      Harpreet Singh, MD

    Discover
  • Read: Webinar Insights: Optimizing Cohort Management in Early-Phase Oncology Trials Webinar Insights: Optimizing Cohort Management in Early-Phase Oncology Trials

    Clinical Trials - Oncology

    Webinar Insights: Optimizing Cohort Management in Early-Phase Oncology Trials

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1744830865620, hs_published_at=1744844126301, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=400,height=400,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rob%20Maiale.jpg',altText='Rob Maiale',fileId=184765575245}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1744843965759, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=51739740}, second={hs_id=181884577650, hs_child_table_id=0, hs_updated_at=1729782746463, hs_published_at=1744844126301, description=Niveda Ramkumar is a seasoned growth strategist with over 15 years of experience in marketing, business development, and account management at leading CROs and life science research firms. She has successfully spearheaded the launch of new services and technologies in clinical development, genomics and biomarkers, regulatory affairs, safety, and commercialization., avatar=Image{width=753,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/niveda-ramkumar.jpg',altText='niveda-ramkumar',fileId=181890014492}, lastname=Ramkumar, hs_initial_published_at=1729782775265, hs_created_by_user_id=26433386, hs_created_at=1729782662277, hs_is_edited=false, hs_deleted_at=0, name=Niveda, job=Director, Marketing, slug=niveda-ramkumar, hs_updated_by_user_id=51739740}, third={}})
    • Rob M. avatar

      Rob M.

    • Niveda R. avatar

      Niveda R.

    Discover
  • Read: Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

    Clinical Trials - Early Phase Research - Oncology

    Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849889, hs_child_table_id=0, hs_updated_at=1723217264651, hs_published_at=1744844126301, avatar=Image{width=320,height=314,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Tai%20Bibbs.jpg',altText='Tai Bibbs',fileId=168843139243}, lastname=Bibbs, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603645564, hs_is_edited=false, hs_deleted_at=0, name=Tai, job=Director, Project Management, slug=tai-bibbs, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Tai Bibbs avatar

      Tai Bibbs

    Discover
  • Read: Clinical Trial Trends: Late Phase Oncology Clinical Trial Trends: Late Phase Oncology

    Clinical Trials - Oncology

    Clinical Trial Trends: Late Phase Oncology

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=180784353404, hs_child_table_id=0, hs_updated_at=1728665282155, hs_published_at=1744844126301, description=Natacha Grand, PhD. is a Senior Operational Strategy Director at Precision for Medicine with a decade of clinical trial experience spanning site, sponsor, and CRO perspectives. Her scientific journey began with a focus on memory T-cells and immune exhaustion before she transitioned to clinical research to drive drug development and enhance patient’s health. Natacha has played critical roles in supporting Phase I-IV clinical trials, particularly in Oncology (Solid tumors and Hematologic malignancies) and chronic viral disease (HIV and HCV) with a focus on patient diversity and decentralized services. ​, avatar=Image{width=2533,height=2669,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Photo%202022_Natacha%20Grand_zoom.jpg',altText='Photo 2022_Natacha Grand_zoom',fileId=180773105730}, lastname=Grand, hs_initial_published_at=1728665285632, hs_created_by_user_id=26433386, hs_created_at=1728665205961, hs_is_edited=false, hs_deleted_at=0, name=Natacha, job=Senior Director, Operational Strategy, slug=natacha-grand, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Natacha Grand avatar

      Natacha Grand

    Discover
  • Read: Clinical Trial Trends: Antibody-Drug Conjugates Clinical Trial Trends: Antibody-Drug Conjugates

    Clinical Trials - Oncology

    Clinical Trial Trends: Antibody-Drug Conjugates

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=180784353404, hs_child_table_id=0, hs_updated_at=1728665282155, hs_published_at=1744844126301, description=Natacha Grand, PhD. is a Senior Operational Strategy Director at Precision for Medicine with a decade of clinical trial experience spanning site, sponsor, and CRO perspectives. Her scientific journey began with a focus on memory T-cells and immune exhaustion before she transitioned to clinical research to drive drug development and enhance patient’s health. Natacha has played critical roles in supporting Phase I-IV clinical trials, particularly in Oncology (Solid tumors and Hematologic malignancies) and chronic viral disease (HIV and HCV) with a focus on patient diversity and decentralized services. ​, avatar=Image{width=2533,height=2669,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Photo%202022_Natacha%20Grand_zoom.jpg',altText='Photo 2022_Natacha Grand_zoom',fileId=180773105730}, lastname=Grand, hs_initial_published_at=1728665285632, hs_created_by_user_id=26433386, hs_created_at=1728665205961, hs_is_edited=false, hs_deleted_at=0, name=Natacha, job=Senior Director, Operational Strategy, slug=natacha-grand, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Natacha Grand avatar

      Natacha Grand

    Discover
  • Read: Clinical Trial Trends: Early Phase Rare Oncology  Clinical Trial Trends: Early Phase Rare Oncology 

    Clinical Trials - Oncology - Rare Diseases

    Clinical Trial Trends: Early Phase Rare Oncology 

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778843, hs_child_table_id=0, hs_updated_at=1714461297945, hs_published_at=1744844126301, description=Robert Bauer is an Executive Director of Operational Strategy at Precision with over 20 years of clinical trial operations experience from both the sponsor and CRO perspectives. He has led teams in the conduct of trials from Phase I through IV and has experience across a wide variety of trial designs. Bob has experience across many therapeutic areas some of which include rare diseases, oncology, depression, schizophrenia, and substance use disorders., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Bauer%20Square.webp',altText='Robert Bauer Square',fileId=165892429961}, linkedin=https://www.linkedin.com/in/robert-bauer-a78b704b, hs_name=, hs_path=, lastname=Bauer, hs_initial_published_at=1716212769184, hs_created_at=1709645745074, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-bauer, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Robert Bauer avatar

      Robert Bauer

    Discover
  • Read: How European Oncology Site Networks Streamline Clinical Trial Site Selection How European Oncology Site Networks Streamline Clinical Trial Site Selection

    Clinical Trials - Oncology

    How European Oncology Site Networks Streamline Clinical Trial Site Selection

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=164713188870, hs_child_table_id=0, hs_updated_at=1714747858916, hs_published_at=1744844126301, description=Deana Demjen is Director of the Precision Site Network, bringing nearly 20 years of clinical research to the role. Most of her previous experience has been in feasibility and site-identification. She has been covering a wide range of therapeutic areas, but her main focus are rare diseases where she is an acting subject matter expert. She is responsible for relationships with PSN sites as well as the maintenance and expansion of the network., avatar=Image{width=650,height=650,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Deana%20Demjen.jpg',altText='Deana Demjen',fileId=164173345152}, lastname=Demjen, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713363112834, hs_is_edited=false, hs_deleted_at=0, name=Deana, job=Director of PSN, slug=deana-demjen, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Deana Demjen avatar

      Deana Demjen

    Discover
  • Read: Clinical Trial Trends: Early Phase Oncology Clinical Trial Trends: Early Phase Oncology

    Clinical Trials - Early Phase Research - Oncology

    Clinical Trial Trends: Early Phase Oncology

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=180784353404, hs_child_table_id=0, hs_updated_at=1728665282155, hs_published_at=1744844126301, description=Natacha Grand, PhD. is a Senior Operational Strategy Director at Precision for Medicine with a decade of clinical trial experience spanning site, sponsor, and CRO perspectives. Her scientific journey began with a focus on memory T-cells and immune exhaustion before she transitioned to clinical research to drive drug development and enhance patient’s health. Natacha has played critical roles in supporting Phase I-IV clinical trials, particularly in Oncology (Solid tumors and Hematologic malignancies) and chronic viral disease (HIV and HCV) with a focus on patient diversity and decentralized services. ​, avatar=Image{width=2533,height=2669,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Photo%202022_Natacha%20Grand_zoom.jpg',altText='Photo 2022_Natacha Grand_zoom',fileId=180773105730}, lastname=Grand, hs_initial_published_at=1728665285632, hs_created_by_user_id=26433386, hs_created_at=1728665205961, hs_is_edited=false, hs_deleted_at=0, name=Natacha, job=Senior Director, Operational Strategy, slug=natacha-grand, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Natacha Grand avatar

      Natacha Grand

    Discover
  • Read: The Dose Dilemma: Lessons from Sotorasib and the Future of Oncology Drug Optimization The Dose Dilemma: Lessons from Sotorasib and the Future of Oncology Drug Optimization

    Clinical Trials - Oncology

    The Dose Dilemma: Lessons from Sotorasib and the Future of Oncology Drug Optimization

    |
      has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1744844126301, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=51739740}, second={}, third={}})
    • Harpreet Singh, MD avatar

      Harpreet Singh, MD

    Discover
Loading...
You've reach the end